Mosliciguat Hits Phase 2 Primary Endpoint in PH-ILD; Phase 3 Underway for Roivant

summarizeSummary

Positive Phase 2 PHocus results for mosliciguat in PH-ILD were announced, showing a -56.3% placebo-adjusted PVR reduction and initiating the Phase 3 PHrontier study.

check_boxKey Events · Product Development and Regulatory · ROIV

• Phase 2 PHocus Primary Endpoint Met

  At Week 16, mosliciguat achieved a -56.3% placebo-adjusted reduction in pulmonary vascular resistance (p<0.0001) — the highest ever reported in a randomized controlled PH trial.

• Secondary Endpoints Also Positive

  Six-minute walk distance improved by +35.2 meters (p=0.0027) and NT-proBNP fell -53.2% (p=0.0002) versus placebo, with effects strengthening to +52.7m and -75.9% at Week 24.

• Phase 3 PHrontier Study Initiated

  The registrational Phase 3 trial is enrolling approximately 375 patients worldwide, with the goal of rapidly advancing mosliciguat toward approval.

• Favorable Safety Profile

  Mosliciguat was well tolerated, with lower cough incidence than placebo (12.1% vs 18.2%) — a key differentiator versus inhaled prostacyclins.

auto_awesomeAnalysis · ROIV · Life Sciences

The Phase 2 PHocus results for mosliciguat delivered the highest pulmonary vascular resistance reduction ever reported in a randomized controlled PH trial (-56.3% placebo-adjusted, p<0.0001), alongside clinically meaningful improvements in six-minute walk distance and NT-proBNP. With the Phase 3 PHrontier study already enrolling, mosliciguat is positioned as a potential first-in-class therapy for a disease with median survival of just 1.5-2 years. This represents a major pipeline de-risking event for a company whose valuation has been driven by LISRAYA's recent FDA approval.